In current months, Wall Avenue has seen a surge of healthcare corporations looking for to go public, as IPO exercise continues to regain momentum after final 12 months’s report lows.  MapLight Therapeutics, Inc. is the newest healthcare firm to leap on the IPO bandwagon, eying a $704 million valuation.
The Providing
In a current submitting with the Securities and Trade Fee, the corporate revealed its intention to supply 14.75 million shares in an preliminary public providing. Put up-IPO, the inventory is predicted to commerce on the Nasdaq inventory alternate underneath the image MPLT. Morgan Stanley, Jefferies, Leerink Companions, and Stifel are the underwriters managing the providing.
The estimated IPO worth is $17 per share, which interprets into internet proceeds of about $227.3 million after deducting providing bills and different expenses. The corporate plans to make use of the proceeds to advance the scientific improvement of its present packages, to fund analysis and improvement actions for added packages, and for working capital and different basic company functions.
Loss Widens
MapLight has not but generated income, because it doesn’t have any product available in the market. Within the six months ended June 30, 2025, the corporate incurred a lack of $52.2 million, in comparison with a loss $37.3 million within the corresponding interval final 12 months. Complete working bills had been $54.2 million within the first half.
MapLight is a clinical-stage biopharmaceutical firm engaged within the discovery of therapies for central nervous system issues. Christopher Kroeger, who co-founded the corporate in 2018, has served as its chief govt officer, president, and member of the board of administrators since then.
Scientific Applications
Presently, MapLight is conducting a phase-II trial evaluating its lead product, ML-007C-MA, for the therapy of acute schizophrenia, and expects topline leads to the second half of 2026. As well as, it’s doing an advanced-stage trial evaluating ML-007C-MA for the therapy of ADP, with topline outcomes anticipated within the second half of 2027.
